Omeprazole formulation
    1.
    发明授权
    Omeprazole formulation 失效
    奥美拉唑制剂

    公开(公告)号:US06174548B1

    公开(公告)日:2001-01-16

    申请号:US09143167

    申请日:1998-08-28

    IPC分类号: A61K928

    摘要: A pharmaceutical composition of omeprazole for oral administration is described which consists essentially of: (a) a tabletted core component containing a therapeutically effective amount of omeprazole, a surface active agent, a filler, a pharmaceutically acceptable alkaline agent and a binder; and (b) a single layer of coating on said core which comprises a layer of an enteric coating agent.

    摘要翻译: 描述了用于口服给药的奥美拉唑的药物组合物,其基本上由以下组成:(a)含有治疗有效量的奥美拉唑,表面活性剂,填充剂,药学上可接受的碱性剂和粘合剂的压片芯组分; 和(b)在所述芯上的单层涂层,其包含一层肠溶包衣剂。

    Pharmaceutical formulation for acid-labile compounds
    5.
    发明授权
    Pharmaceutical formulation for acid-labile compounds 有权
    酸不稳定化合物的药物制剂

    公开(公告)号:US06602522B1

    公开(公告)日:2003-08-05

    申请号:US09597206

    申请日:2000-06-20

    IPC分类号: A61K936

    摘要: A pharmaceutical composition of omeprazole for oral administration is described which includes: (a) a tabletted core component containing a therapeutically effective amount of a acid-labile compound, e.g., substituted benzamidazole such as omeprazole, an optional surface active agent, a filler, a pharmaceutically acceptable alkaline agent, and a binder; and (b) a single layer of coating on said core which comprises a layer of an enteric coating agent.

    摘要翻译: 描述了用于口服给药的奥美拉唑的药物组合物,其包括:(a)含有治疗有效量的酸不稳定化合物的压片核心组分,例如取代的苯甲胺唑,例如奥美拉唑,任选的表面活性剂,填充剂, 药学上可接受的碱性试剂和粘合剂; 和(b)在所述芯上的单层涂层,其包含一层肠溶包衣剂。

    Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor

    公开(公告)号:US06544556B1

    公开(公告)日:2003-04-08

    申请号:US09659222

    申请日:2000-09-11

    IPC分类号: A61K920

    摘要: An oral solid dosage form includes a therapeutically effective amount of an NSAID and a proton pump inhibitor in an amount effective to inhibit or prevent gastrointestinal side effects normally associated with the NSAID. Also disclosed is a method of treating a human patient in need of antiinflammatory, analgesic and/or antipyretic therapy, comprising orally administering to the patient an oral pharmaceutical dosage form which includes a therapeutically effective amount of an NSAID and an amount of a proton pump inhibitor effective to substantially inhibit gastrointestinal side effects of the NSAID. The invention is further related to a method of prophylactically treating a human patient who is on a therapy known to have significant gastrointestinal side effects or is about to begin such a therapy, via concurrent administration of an NSAID and a proton pump inhibitor in a combination (single) oral dosage form.